Promising early results for avelumab plus radiation in leptomeningeal disease In a small but encouraging phase 1B study, researchers at Moffitt Cancer Center report that the immunotherapy drug avelumab, when given with whole-brain radiotherapy, may offer a new, potentially safer and more effective option for leptomeningeal disease (LMD). The findings, published in Neuro-Oncology, come from…